Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria
Open Access
- 1 January 2009
- journal article
- research article
- Published by Elsevier in Cell Host & Microbe
- Vol. 5 (1), 95-105
- https://doi.org/10.1016/j.chom.2008.12.004
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Single-Dose Protection againstPlasmodium bergheiby a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron AJournal of Virology, 2008
- Malaria: progress, perils, and prospects for eradicationJournal of Clinical Investigation, 2008
- Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical TrialPLOS ONE, 2008
- Asexual blood-stage malaria vaccine development: facing the challengesCurrent Opinion in Infectious Diseases, 2007
- Cytokine responses of CD4+ T cells during a Plasmodium chabaudi chabaudi (ER) blood-stage infection in mice initiated by the natural route of infectionMalaria Journal, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Insecticide-treated bed nets and curtains for preventing malariaCochrane Database of Systematic Reviews, 2004
- Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect thein vivoantibody responseEuropean Journal of Immunology, 2004
- Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in MiceInfection and Immunity, 2001
- Common West African HLA antigens are associated with protection from severe malariaNature, 1991